Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS Australia (SA) Inc
 
 
Facebook
 
ME/CFS AUSTRALIA (SA) INC

Registered Charity 3104

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 28,
Hindmarsh,
South Australia 5007

Office:
Suite 506,
North Terrace House,
19 North Terrace,
Hackney, SA, 5069


Phone:
1300 128 339

Office Hours:
Wednesdays, 11am-3pm

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
PDF Application Form (PDF, 242KB)
Why become a member?
 

Validation of new symptom-based Fibromyalgia criteria for IBS co-morbidity studies

Sunday 20 March 2011

ProHealth

ProHealth reports:

 

Validation of New Symptom-Based Fibromyalgia Criteria for Irritable Bowel Syndrome Co-morbidity Studies – Source: Journal of Neurogastroenterology and Motility, Jan 2011

by Ami D Sperber, et al.
March 12, 2011

[Note: To read the full text of this open access article free, click HERE.  See also the free editorial: “Why should gastroenterologists know about fibromyalgia? Common pathogenesis and clinical implications.”]

Background/Aims: There is significant co-morbidity between irritable bowel syndrome (IBS) and fibromyalgia syndrome (FMS). [Roughly one third of IBS patients have FMS & half of FM patients have IBS.] However, FMS is diagnosed by physical examination, which limits the conduct of co-morbidity studies in a large population-based study. The purpose of this study was to determine the diagnostic validity of new symptom-based criteria in patients with FMS and/or IBS using the American College of Rheumatology (ACR) criteria as a gold standard.

Methods: The study participants consisted of women with FMS (n = 30), IBS (n = 27) and controls (n = 28).

• New symptom-based diagnostic criteria for FMS [included] a regional pain scale and a visual analogue scale for fatigue. [For background, see “ACR explains proposed new fibromyalgia diagnostic criteria,”  May 2010.]

• All subjects underwent a physical examination for FMS (ACR criteria) and structured questionnaires of regional pain scale and visual analogue scale for fatigue.

• A fibromyalgia intensity score was calculated and thresholds of tenderness were determined by a dolorimeter.

Results:

• The number of participants diagnosed with FMS in the entire study population (n = 85) was 31 by the new criteria.

• Compared to the ACR, the sensitivity of the new criteria was 82.9%, specificity 96.0%, positive predictive value 93.5% and negative predictive value 88.9%.

• In addition, new criteria were useful for the diagnosis of FMS among the subjects with IBS.

• A fibromyalgia intensity score was significantly correlated with the threshold of tenderness (r = -0.62, P < 0.001).

Conclusions: The new symptom-based diagnostic criteria for the diagnosis of FMS can be used in large-scale clinical and epidemiological co-morbidity studies, in which physical examination is unfeasible. Gastroenterologists investigating the effects of co-morbid FMS in IBS patients can use these new criteria with confidence.

Source: Journal of Neurogastroenterology and Motility, Jan 2011. PMID: 21369494, by Sperber AD, Akiva S, Leshno M, Halpern Z, Buskila D. Department of Gastroenterology, Soroka Medical Center, Beer-Sheva, Israel. [Email:amy@bgu.ac.il]

 

The above originally appeared here.

 


Arrow right

More Fibromyalgia News

 


 

blog comments powered by Disqus

Previous Previous Page